MOSCOW (Sputnik) – The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to the ministry’s register.
“An open study of the safety, tolerability, reactogenicity and immunising power of the EpiVacCorona-N peptide antigen-based vaccine for preventing COVID, involving volunteers aged 18-60 (phase 1-2),” the register read.
The trials started on April 8 and are set to end on September 30.
The EpiVacCorona vaccine, developed by the Vector State Research Centre of Virology and Biotechnology, is a peptide-based drug that relies on a promising synthetic platform. It consists of artificially synthesised short fragments of viral proteins – peptides, through which the immune system learns how to recognise and then neutralise the virus.
Sourse: sputniknews.com
0.00 (0%) 0 votes
MOSCOW (Sputnik) - The Coalition for the Restoration of Democracy (CORED), which unites 18 opposition parties in Guinea, said on…
The news of an interplanetary scale comes after NASA believed it had captured its first sample with Perseverance last month,…
MOSCOW (Sputnik) - The last pipe of the second string of Nord Stream 2 has been welded, and after a…
LONDON (Sputnik) – The UK government on Monday condemned the military coup against the president of Guinea, Alpha Conde, and…